Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and...
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease )
Also on site :
- Ukraine doing West’s ‘dirty work’ in Africa – Sudanese official
- 'He knows where to find me,' Newsom responds to Trump administration arrest threat
- Two people killed by falling trees and thousands without power after storms sweep southern states